<DOC>
	<DOCNO>NCT00459381</DOCNO>
	<brief_summary>This phase II trial study side effect well pazopanib work treat patient recurrent glioblastoma . Pazopanib may stop growth tumor cell block enzymes need cell growth block blood flow tumor</brief_summary>
	<brief_title>Pazopanib Treating Patients With Recurrent Glioblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine therapeutic efficacy pazopanib hydrochloride , measure 6-month progression-free survival ( PFS ) , patient recurrent glioblastoma . II . Determine safety profile drug patient . SECONDARY OBJECTIVES : I . Determine efficacy drug , measure radiographic response , time progression , overall survival , patient . OUTLINE : This multicenter study . Patients receive oral pazopanib hydrochloride daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically least 2 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<criteria>Histologically confirm glioblastoma multiforme , include gliosarcoma Recurrent disease Must unequivocal radiographic evidence tumor progression MRI , define follow : 25 % increase sum product measurable lesion small sum observe ( baseline decrease ) use technique baseline Clear worsen evaluable disease Appearance new lesion site Clear clinical worsening Must fail prior radiotherapy complete ≥ 42 day ago Patients receive prior therapy include interstitial brachytherapy stereotactic radiosurgery must confirmation true progressive disease , rather radiation necrosis , base positron emission tomography ( PET ) scan , thallium scanning , magnetic resonance spectroscopy , surgical documentation disease Treatment 2 prior relapse allow Relapse define progression follow initial therapy ( i.e. , radiotherapy without chemotherapy , use initial therapy ; therefore 3 prior therapy [ initial therapy therapy 2 relapse ] allow ) If patient surgical resection relapse disease anticancer therapy institute 12 week , patient undergoes another surgical resection , consider 1 relapse For patient prior therapy lowgrade glioma , surgical diagnosis glioblastoma multiforme consider first relapse Karnofsky performance status 60100 % Life expectancy &gt; 8 week WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 10 g/dL ( may reach transfusion ) Platelet count ≥ 100,000/mm^3 PT/INR/PTT ≤ 1.2 time upper limit normal ( ULN ) SGOT &lt; 2.5 time ULN Bilirubin &lt; 2.5 time ULN Creatinine &lt; 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min Urine protein : creatinine ratio &gt; 1 OR urine protein &lt; 1,000 mg 24hour urine collection OR proteinuria &lt; 1+ Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublebarrier contraception study therapy OR practice abstinence sexual intercourse 14 day prior , , ≥ 21 day study therapy Systolic blood pressure ( BP ) ≤ 140 mm Hg diastolic BP ≤ 90 mm Hg Prior initiation adjustment BP medication allow provided average 3 BP reading ≤ 140/90 mm Hg No uncontrolled significant medical illness would preclude study therapy No condition , include follow : Serious nonhealing wound , ulcer , bone fracture Abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 28 day Cerebrovascular accident ( CVA ) within past 6 month Myocardial infarction , cardiac arrhythmia , admission unstable angina , cardiac angioplasty , stenting within past 84 day Venous thrombosis within past 84 day New York Heart Association ( NYHA ) class III IV heart failure Asymptomatic NYHA class II heart failure treatment allow No cancer except nonmelanoma skin cancer carcinoma situ cervix unless complete remission therapy disease ≥ 3 year No disease would obscure toxicity dangerously alter drug metabolism No history allergic reaction attribute compound similar chemical biological composition pazopanib hydrochloride agents No QTc prolongation ( i.e. , QTc interval ≥ 500 msec ) significant ECG abnormalities No condition impair ability swallow retain pazopanib hydrochloride , include follow : Gastrointestinal tract disease result inability take oral medication Requirement IV alimentation Prior surgical procedure affect absorption Active peptic ulcer disease See Disease Characteristics Recovered prior therapy At least 28 day since prior resection recurrent progressive tumor recover Residual disease resection recurrent glioblastoma mandate eligibility study More 7 day since prior noncytotoxic agent ( e.g. , interferon , tamoxifen , thalidomide , isotretinoin ) Radiosensitizers allow More 14 day since prior investigational agent More 14 day since prior vincristine More 21 day since prior procarbazine More 28 day since prior cytotoxic therapy More 42 day since prior nitrosoureas No prior bevacizumab No prior sorafenib tosylate sunitinib malate No prior pazopanib hydrochloride No concurrent CYP2C9 substrate , include follow : Anticoagulants ( e.g. , warfarin [ therapeutic dos ] ) Oral hypoglycemics ( e.g. , glipizide , glyburide , tolbutamide , glimepiride , nateglinide ) Ergot derivative ( e.g. , dihydroergotamine , ergonovine , ergotamine , methylergonovine ) Neuroleptics ( e.g. , pimozide ) Erectile dysfunction agent ( e.g. , sildenafil , tadalafil , vardenafil ) Antiarrhythmics ( e.g. , bepridil , flecainide , lidocaine , mexilitine , amiodarone , quinidine , propafenone ) Immune modulators ( e.g. , cyclosporine , tacrolimus , sirolimus ) Miscellaneous drug ( e.g. , theophylline , quetiapine , risperidone , tacrine , clozapine , atomoxetine ) No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer therapy ( include chemotherapy , radiotherapy , hormonal treatment , immunotherapy ) investigational drug No concurrent enzymeinducing antiepileptic drug ( EIAEDs ) NonEIAEDs allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>